Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQB 3122

Next Previous
Drug Profile

TQB 3122

Alternative Names: TQB-3122

Latest Information Update: 13 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics
  • Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 22 Jan 2026 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT07269145)
  • 14 Dec 2025 Preclinical trials in Solid tumours in China (PO) prior to December 2025
  • 08 Dec 2025 Chia Tai Tianqing Pharmaceutical Group plans a phase I trial for Solid tumors (Late-stage disease) in China (PO, capsule) in December 2025 (NCT07269145)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top